Something went wrong with the connection!

Retinitis Pigmentosa Pipeline Therapies driving the Market Forward

 Breaking News
  • No posts were found

Retinitis Pigmentosa Pipeline Therapies driving the Market Forward

May 27
12:28 2020
Retinitis Pigmentosa Pipeline Therapies driving the Market Forward

Retinitis Pigmentosa Pipeline | RP Pipeline
Several pharma and biotech companies including HORA-RPE65 (Horama), AAV8-RPGR (Nightstar Therapeutics), jCell (jCyte), Renexus (NT-501; Neurotech Pharmaceuticals), and hRPC (ReNeuron Limited) are expected to enter into Retinitis pigmentosa market in the coming decade.

Retinitis Pigmentosa Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Retinitis Pigmentosa market. A detailed picture of the Retinitis Pigmentosa pipeline landscape is provided, which includes the disease overview and Retinitis Pigmentosa treatment guidelines.

Disease Overview

Retinitis pigmentosa is a heterogeneous, progressive disease that leads to worsening of the vision with time.

Although, there is a significant variation in the age of onset, progression rate, the involvement of rod, and cone, retinal cells deterioration, however; the clinical manifestations that are kept in mind while diagnosing are night blindness, progressive loss of peripheral vision and subsequent loss of central vision.

Request for Sample Pages.

The assessment part of the report embraces in-depth Retinitis Pigmentosa commercial assessment and clinical assessment of the Retinitis Pigmentosa pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Retinitis Pigmentosa collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

Retinitis Pigmentosa Market

Present available options and approaches in the Retinitis pigmentosa market are limited. Hence, a number of clinical trials are underway, and a lot of novel therapies are poised to enter the Retinitis pigmentosa therapy market.

Several pharma and biotech companies including HORA-RPE65 (Horama), AAV8-RPGR (Nightstar Therapeutics), jCell (jCyte), Renexus (NT-501; Neurotech Pharmaceuticals), and hRPC (ReNeuron Limited) are expected to enter into Retinitis pigmentosa market in the coming decade.

The robust pipeline is anticipated to bring a significant shift in the Retinitis pigmentosa market in the 7MM. Moreover, the US is expected to grab the major chunk of Retinitis pigmentosa market share as compared to other members of 7MM.

Click to Know More about the Report.

 

The Retinitis Pigmentosa market outlook of the report helps to build a detailed comprehension of the historic, current and forecasted Retinitis Pigmentosa market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology.

According to DelveInsight, Retinitis Pigmentosa 7MM market is expected to change in the study period 2017–2030.

Emerging Therapies

HORA-RPE65: Horama

AAV8-RPGR/BIIB112: Nightstar Therapeutics/Biogen

jCell: jCyte

Renexus: Neurotech

Cenegermin: Dompé Farmaceutici

hRPC Cells: ReNeuron

UshStat: Sanofi (Terminated)

AGN-151597: Allergan

AAV-RPGR: MeiraGTx

AAV-RPE65: MeiraGTx

Visit to Know More.

Scope of the report

  • The Retinitis Pigmentosa report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Retinitis Pigmentosa across the complete product development cycle, including all clinical and nonclinical stages.
  • It comprises of detailed profiles of Retinitis Pigmentosa therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
  • Detailed Retinitis Pigmentosa research and development progress and trial details, results wherever available, are also included in the pipeline study.
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Retinitis Pigmentosa.

 

Table of Contents

1. Report Introduction

2. Retinitis Pigmentosa 

3. Retinitis Pigmentosa Current Treatment Patterns

4. Retinitis Pigmentosa – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Retinitis Pigmentosa Late Stage Products (Phase-III)

7. Retinitis Pigmentosa Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Retinitis Pigmentosa Discontinued Products

13. Retinitis Pigmentosa Product Profiles

14. Retinitis Pigmentosa Key Companies

15. Retinitis Pigmentosa Key Products

16. Dormant and Discontinued Products

17. Retinitis Pigmentosa Unmet Needs

18. Retinitis Pigmentosa Future Perspectives

19. Retinitis Pigmentosa Analyst Review  

20. Appendix

21. Report Methodology

 

About DelveInsight

DelveInsight is a premier Business Consulting and Market Research firm focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for better growth in the market.  

Browse through our vast repository

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Vinita Rakheja
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: www.delveinsight.com/

Related Articles

Calendar

September 2020
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  

Categories